We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

283 hedge funds and large institutions have $4.38B invested in Intra-Cellular Therapies Inc. in 2022 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 94 increasing their positions, 94 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 36

14% more capital invested

Capital invested by funds: $3.85B → $4.38B (+$534M)

3% more funds holding

Funds holding: 274 → 283 (+9)

0% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 94

14% less funds holding in top 10

Funds holding in top 10: 7 → 6 (-1)

20% less call options, than puts

Call options by funds: $16.9M | Put options by funds: $21M

Holders
283
Holders Change
+9
Holders Change %
+3.28%
% of All Funds
4.55%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.1%
New
48
Increased
94
Reduced
94
Closed
36
Calls
$16.9M
Puts
$21M
Net Calls
-$4.11M
Net Calls Change
-$6.53M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$88.1M
2
JP Morgan Chase
JP Morgan Chase
New York
+$65.7M
3
Citadel Advisors
Citadel Advisors
Florida
+$23.9M
4
BlackRock
BlackRock
New York
+$17.4M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$12.6M

Top Sellers

Rank Fund Capital Flow
1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$56.7M
2
APM
Avidity Partners Management
Texas
-$45M
3
WA
Wasatch Advisors
Utah
-$25.2M
4
SC
Samlyn Capital
New York
-$25M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$23.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
IMRF
301
Illinois Municipal Retirement Fund
Illinois
– -$470K -10,091 Closed
SWM
302
SeaCrest Wealth Management
New York
– -$423K -9,090 Closed
FRM
303
Fox Run Management
Connecticut
– -$389K -8,357 Closed
LP
304
LMR Partners
United Kingdom
– -$368K -7,900 Closed
BHCM
305
Boulder Hill Capital Management
New York
– -$349K -7,500 Closed
CP
306
CenterBook Partners
Connecticut
– -$312K -6,701 Closed
CC
307
Cipher Capital
New York
– -$247K -5,308 Closed
ACM
308
AlphaCrest Capital Management
New York
– -$232K -4,982 Closed
RJT
309
Raymond James Trust
Florida
– -$208K -4,467 Closed
FAIM
310
Financial Advocates Investment Management
Washington
– -$466K -2,788 Closed
QT
311
Quantbot Technologies
New York
– -$55K -1,189 Closed
GWSG
312
GPS Wealth Strategies Group
Colorado
– -$47K -1,000 Closed
IA
313
IFP Advisors
Florida
– -$10K -401 Closed
DFCM
314
Dark Forest Capital Management
Puerto Rico
– -$5K -114 Closed
EW
315
Evoke Wealth
California
– -$5K -110 Closed
9 10 11 12
13

ITCI Hedge Fund Activity: Q4 2022 in Review

283 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2022, worth a combined $4.38B — up 14% from $3.85B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new ITCI positions and 36 closed out — a net gain of 12 holders — while 94 added to existing stakes and 94 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $88.1M. The largest seller was Lord, Abbett & Co, cutting an estimated $56.7M.

  • 283 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2022, up from 274 in Q3 2022.
  • Funds reported $4.38B of Intra-Cellular Therapies Inc. stock for Q4 2022, up 14% quarter-over-quarter.
  • 48 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2022 and 36 closed out, a net change of +12 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q4 2022 was Fidelity Investments, an estimated $88.1M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q4 2022 was Lord, Abbett & Co, an estimated $56.7M sold.

Based on aggregated 13F filings for Q4 2022.